Cancers of the breast, endometrium and ovary can display endocrine sensitivity—and a proportion of such tumours regress when deprived of hormones (Hawkins & Miller, 1988). As a consequence, endocrine deprivation therapy is a major treatment modality, particularly in patients with breast cancer (Miller, 1990).
Given that endocrine factors also play a critical role in the aetiology of certain tumours (Preston-Martin, Pike, Ross et al. 1990), hormone manipulation might also prevent cancer. Initiatives attempting hormone-prevention of cancer have been given impetus by the availability of relatively non-toxic drugs such as luteinizing hormone-releasing hormone (LHRH) agonists and antioestrogens which block hormone action without the morbidity and irreversibility of surgical and radiological procedures. In this commentary we evaluate current thinking behind the use of hormone suppressant drugs as a method of prevention of cancer and conclude that such an approach is feasible but, in parallel with steroid contraception, there are important long-term consequences
Journal of Endocrinology is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
| Sept 2018 onwards | Past Year | Past 30 Days | |
|---|---|---|---|
| Full Text Views | 5 | 0 | 0 |
| PDF Downloads | 0 | 0 | 0 |
Online ISSN: 1479-6805
Print ISSN: 0022-0795
Strengthening biomedical communities
to advance science and health
CONTACT US
Bioscientifica Ltd | Starling House | 1600 Bristol Parkway North | Bristol BS34 8YU | UK
Bioscientifica Ltd | Registered in England no 3190519
